Potent inhibitors of human inosine monophosphate dehydrogenase type II. Fluorine-substituted analogues of thiazole-4-carboxamide adenine dinucleotide

Article abstract of DOI:10.1021/jm00007a007

Three analogues of thiazole-4-carboxamide adenine dinucleotide (TAD) (1- 3) containing a fluorine atom at the C2' of the adenine nucleoside (in the ribo and arabino configuration) and at the C3' (in the ribo configuration) were synthesized in high yield from the corresponding 5'-monophosphates of 2'-deoxy-2'-fluoroadenosine (9), 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)- adenine (17), and 3'-deoxy-3'-fluoroadenosine (14), respectively. Pure 2',3'- O-isopropylidene-tiazofurin 5'-phosphorimidazolide (8) was obtained by phosphorylation of the protected tiazofurin followed by treatment with carbonyldiimidazole and HPLC purification. Reaction of 8 with 9 in DMF-d₇ (monitored by ¹H and ³¹P NMR) afforded the desired dinucleotide 12, which after deisopropylidenation gave 1 in 82% yield. Small amounts of symmetrical dinucleotides AppA (10, 7.2%) and TRppTR (11, 8.0%) were also isolated during HPLC purification of the major product 12. In a similar manner, compounds 2 and 3 were obtained by coupling of 8 with 14 and 17 in 80% and 76% yield, respectively. All newly prepared fluoro-substituted compounds as well as β- CF₂-TAD, earlier synthesized by us, showed good inhibitory activity against inosine monophosphate dehydrogenase type II, the isozyme which is predominant in neoplastic cells. Binding of 1 (K(is) = 0.5 μM), 2 (K(is) = 0.7 μM), and 3 (K(is) = 2.9 μM) was comparable to that of TAD (K(i) = 0.2 μM). The difluoromethylene bisphosphonate analogue, β-CF₂-TAD (K(i) = 0.17 μM), was found to be equally effective as the best cofactor-type inhibitor, β-CH₂- TAD (K(i) = 0.11 μM). Interestingly, the level of inhibition of horse liver alcohol dehydrogenase by these compounds was found to be much lower (0.1 mM for 1 and 2 and no inhibition up to 10 mM for 3). These findings show that inhibition of tumor-induced inosine monophosphate dehydrogenase type II is selective and may be of therapeutic interest.